Efficacy and safety of a single intracavernous injection of autologous adipose-derived stem cells for post radical prostatectomy erectile dysfunction

Single intracavernous injection of autologous adipose-derived stem cells for post radical prostatectomy erectile dysfunction - SIPRPED

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000050898

Enrollment

Registered

2023-04-20

Start date

2020-01-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erectile Dysfunction

Interventions

Treatment group receiving a single intracavernous injection of ADSC post RP and kept on PDE5i Patients received only PDE5i

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Males operated by RP with the none-nerve sparing technique. All patients were potent before RP. The same urologist performed the RPs.

Exclusion criteria

Exclusion criteria: Impotent males before RP

Design outcomes

Primary

Measure	Time frame
Erectile function (EF) was tested using the IIEF-5 score after intracorporal injection of ADSCs	—

Secondary

Measure	Time frame
Assess safety of ADSC therapy	—

Countries

Asia(except Japan)

Contacts

Public ContactMohamad Abou Chakra

Al Zahraa Hospital Urology

mohamadabouchakra@hotmail.com+96171613732

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026